Role of IL-17A in the development of colitis-associated cancer

Carcinogenesis

Volumn 33, Issue 4, 2012, Pages 931-936

  Hyun, Yil Sik ^a   Han, Dong Soo ^a   Lee, A Reum ^a   Eun, Chang Soo ^a   Youn, Jeehee ^a   Kim, Ho Youn ^b  

^a Hanyang University College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; BETA CATENIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN E; DEXTRAN SULFATE; GAMMA INTERFERON; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 17; INTERLEUKIN 6; KI 67 ANTIGEN; PROTEIN KINASE B; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; COLITIS ASSOCIATED CANCER; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; WILD TYPE;

EID: 84859602743     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs106     Document Type: Article

References (35)

1. Watanabe, T. et al. (2011) Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflamm. Bowel Dis., 17, 802-808.
2. Feagins, L. A. et al. (2009) Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat. Rev. Gastroenterol. Hepatol., 6, 297-305.
3. Lakatos, P. L. et al. (2008) Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J. Gastroenterol., 14, 3937-3947.
4. Fearon, E. R. et al. (1990) A genetic model for colorectal tumorigenesis. Cell, 61, 759-767.
5. Morin, P. J. et al. (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science, 275, 1787-1790.
6. Kraus, S. et al. (2009) Inflammation and colorectal cancer. Curr. Opin. Pharmacol., 9, 405-410.
7. Abraham, C. et al. (2009) Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm. Bowel Dis., 15, 1090-1100.
8. Koenders, M. I. et al. (2010) Translationalmini-review series on Th17 cells: are T helper 17 cells really pathogenic in autoimmunity? Clin. Exp. Immunol., 159, 131-136.
9. Brand, S. (2009) Crohn's disease: th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut, 58, 1152-1167.
10. O'Connor, W. Jr et al. (2009) A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat. Immunol., 10, 603-609.
11. Ito, R. et al. (2008) Involvement of IL-17A in the pathogenesis of DSSinduced colitis in mice. Biochem. Biophys. Res. Commun., 377, 12-16.
12. Wu, S. et al. (2009) A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med., 15, 1016-1022.
13. Chae, W. J. et al. (2010) Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc. Natl Acad. Sci. USA, 107, 5540-5544.
14. Nakae, S. et al. (2002) Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity, 17, 375-387.
15. Balkwill, F. et al. (2001) Inflammation and cancer: back to Virchow? Lancet, 357, 539-545.
16. El-Omar, E. M. et al. (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature, 404, 398-402.
17. Lanas, A. (2009) Nonsteroidal antiinflammatory drugs and cyclooxygenase inhibition in the gastrointestinal tract: a trip from peptic ulcer to colon cancer. Am. J. Med. Sci., 338, 96-106.
18. Sun, J. et al. (2005) Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J. Natl Cancer Inst., 97, 525-532.
19. Warzocha, K. et al. (1998) Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood, 91, 3574-3581.
20. He, D. et al. (2010) IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloidderived suppressor cells. J. Immunol., 184, 2281-2288.
21. Kryczek, I. et al. (2009) Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood, 114, 357-359.
22. Martin-Orozco, N. et al. (2009) T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity, 31, 787-798.
23. Numasaki, M. et al. (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood, 101, 2620-2627.
24. Wang, L. et al. (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med., 206, 1457-1464.
25. Fukata, M. et al. (2008) The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease. J. Immunol., 180, 1886-1894.
26. Malhotra, N. et al. (2010) SMAD2 is essential for TGF beta-mediated Th17 cell generation. J. Biol. Chem., 285, 29044-29048.
27. Kryczek, I. et al. (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood, 114, 1141-1149.
28. Kryczek, I. et al. (2007) Cutting edge: th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol., 178, 6730-6733.
29. Su, X. et al. (2010) Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J. Immunol., 184, 1630-1641.
30. Nelson, W. J. et al. (2004) Convergence of Wnt, beta-catenin, and cadherin pathways. Science, 303, 1483-1487.
31. Lee, G. et al. (2010) Phosphoinositide 3-kinase signaling mediates betacatenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology, 139, 869-881.
32. Sturlan, S. et al. (2001) Interleukin-10-deficient mice and inflammatory bowel disease associated cancer development. Carcinogenesis, 22, 665-671.
33. Grivennikov, S. et al. (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell, 15, 103-113.
34. Li, B. et al. (2009) Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res., 69, 338-348.
35. Balkwill, F. (2009) Tumour necrosis factor and cancer. Nat. Rev. Cancer, 9, 361-371.